PriceTargets.com logo

Cano Health - CANO Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $1.85
  • Forecasted Upside: ∞
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/5/2024 09:39 AM ET
+0 (0.00%)
Get New Cano Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CANO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CANO

Analyst Price Target is $1.85
▲ +∞ Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cano Health in the last 3 months. The average price target is $1.85, with a high forecast of $3.75 and a low forecast of $0.80. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for CANO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 3 contributing investment analysts is to reduce stock in Cano Health. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2023UBS GroupReiterated RatingNeutral ➝ Sell$12.00 ➝ $3.75Low
8/11/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
8/11/2023CitigroupDowngradeBuy ➝ Neutral$4.00 ➝ $0.80Low
5/16/2023Piper SandlerBoost Target$1.00Low
5/12/2023CitigroupLower Target$5.00 ➝ $4.00Low
1/6/2023UBS GroupDowngradeBuy ➝ Neutral$12.00 ➝ $1.25Low
1/5/2023Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
12/13/2022Bank of AmericaReiterated RatingUnderperform$1.50Low
11/28/2022Credit Suisse GroupLower Target$4.00Low
11/16/2022CitigroupLower TargetBuy$7.00 ➝ $5.00Low
11/10/2022CowenDowngradeOutperform ➝ Market Perform$10.00 ➝ $3.00Low
11/10/2022CowenDowngradeOutperform ➝ Market Perform$10.00 ➝ $3.00Low
11/10/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
10/27/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$10.00 ➝ $5.00Low
9/23/2022Bank of AmericaDropped CoverageNeutralN/A
9/7/2022Truist FinancialInitiated CoverageHold$7.00Low
8/10/2022CitigroupLower Target$8.00 ➝ $7.00Low
6/24/2022Raymond JamesInitiated CoverageOutperform$8.00Low
6/15/2022Bank of AmericaDowngradeBuy ➝ Neutral$8.00 ➝ $6.00High
5/17/2022UBS GroupLower TargetNA$14.00High
5/10/2022Piper SandlerLower Target$5.00 ➝ $4.00Medium
5/10/2022CowenLower Target$13.00 ➝ $10.00High
5/10/2022CowenLower Target$13.00 ➝ $10.00High
5/10/2022CitigroupLower Target$10.00 ➝ $8.00High
5/3/2022Bank of AmericaInitiated CoverageBuy$8.00High
4/20/2022UBS GroupInitiated CoverageBuy$15.00High
4/6/2022Piper SandlerDowngradeNeutral ➝ Underweight$8.50 ➝ $5.00High
3/16/2022Credit Suisse GroupLower TargetOutperform$15.00 ➝ $13.00High
3/16/2022CitigroupLower Target$12.00 ➝ $10.00High
12/7/2021CowenLower TargetOutperform$18.00 ➝ $15.00Medium
11/10/2021Piper SandlerBoost TargetNeutral$11.00 ➝ $13.00High
10/20/2021Jefferies Financial GroupInitiated CoverageBuy$17.00High
10/19/2021Piper SandlerInitiated CoverageNeutralLow
10/1/2021Wolfe ResearchInitiated CoverageOutperform$19.00High
9/21/2021CitigroupInitiated CoverageBuy$20.00High
9/9/2021CowenInitiated CoverageOutperform$18.00High
8/2/2021Credit Suisse GroupInitiated CoverageOutperform$18.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 2 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 2 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cano Health logo
Cano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $3.81
Low: $2.00
High: $9.31

52 Week Range

Now: N/A

Volume

159,142 shs

Average Volume

423,785 shs

Market Capitalization

$12.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Cano Health?

The following Wall Street analysts have issued stock ratings on Cano Health in the last year: Citigroup Inc., Jefferies Financial Group Inc., Piper Sandler, and UBS Group AG.
View the latest analyst ratings for CANO.

What is the current price target for Cano Health?

3 Wall Street analysts have set twelve-month price targets for Cano Health in the last year. Their average twelve-month price target is $1.85. UBS Group AG has the highest price target set, predicting CANO will reach $3.75 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $0.80 for Cano Health in the next year.
View the latest price targets for CANO.

What is the current consensus analyst rating for Cano Health?

Cano Health currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for CANO.

What other companies compete with Cano Health?

Other companies that are similar to Cano Health include ETAO International, Purple Biotech, Centogene, Imunon and NantHealth. Learn More about companies similar to Cano Health.

How do I contact Cano Health's investor relations team?

Cano Health's physical mailing address is 1601 WASHINGTON AVENUE SUITE 800, MIAMI BEACH FL, 33139. The company's listed phone number is 855-226-6633 and its investor relations email address is [email protected]. The official website for Cano Health is canohealth.com. Learn More about contacing Cano Health investor relations.